On April 22 2013 BioInvent reported that the first patient has been treated in a phase II study of the drug candidate BI-505, developed for the treatment of multiple myeloma (Press release BioInvent, APR 22, 2013, http://www.bioinvent.com/investors/press-releases/release.aspx?releaseid=765492 [SID:1234500564]). The study is conducted in patients with asymptomatic myeloma (called "smoldering multiple myeloma"). Smoldering myeloma patients have not developed symptoms of disease and the condition can be detected only in laboratory tests. The current study involves up to 10 patients and evaluates disease activity following treatment with BI-505. Secondary objectives include safety, pharmacokinetics and assessment of biomarkers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!